Share:
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE)
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) (the Company or PAVmed ), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release using its CarpX
® minimally invasive carpal tunnel device.
CarpX relieves the symptoms of Carpal Tunnel Syndrome (CTS) in a rapid, minimally invasive, office-based procedure that speeds patients recovery. CTS is a common workplace-related condition that causes chronic pain to patients and, as the top driver of workmen s compensation claims, imposes high costs on society.
The patient presented with symptoms of carpal tunnel syndrome to Dr. Edward J. Armbruster of Mercer-Bucks Orthopaedics, P.C., in greater Philadelphia, who performed minimally invasive carpal tunnel release using the CarpX device. In marked contrast to typical recovery times of up to several months following conventiona
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under .
PAVmed Inc.January 8, 2021 GMT
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of 6.0 million shares of common stock at a price of $2.24 per share which was priced at-the-market under Nasdaq rules.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. PAVmed plans to use the net proceeds for working capital, general corporate purposes, and to repay a portion of certain of the Company’s outstanding convertible not
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. The Offering is expected to close on or about January 8, 2021 subject to the satisfaction of customary closing conditions.
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of approximately 5.1 million shares of common stock at a price of $1.60 per share.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $7.4 million after deducting the placement agents’ fees and other estimated offering expenses. PAVmed plans to use the net proceeds for working capital, general corporate purposes, and to repay a portion of certain of the Company’s outstanding convertible notes.
PAVmed Announces Registered Direct Offering of its Common Stock apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.